 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Alpine Immune Sciences, Inc. (ALPN) operates as a clinical-stage biopharmaceutical company.
It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases.
The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias.
The company was incorporated in 2007 and is headquartered in Seattle, Washington.
Entry Point: $64.25
Trading Range: $6.71 - $64.70
Stop Loss: $61.00
Target Price: $70.60
